Currently out of the existing stock ratings of Whitney Ijem, 83 are a BUY (77.57%), 18 are a HOLD (16.82%), 6 are a SELL (5.61%).

Whitney Ijem

Work Performance Price Targets & Ratings Chart

Analyst Whitney Ijem, currently employed at CANACCORD, carries an average stock price target met ratio of 38.48% that have a potential upside of 22.64% achieved within 221 days.

Whitney Ijem’s has documented 212 price targets and ratings displayed on 19 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on VRTX, Vertex Pharmaceuticals at 06-Aug-2025.

Wall Street Analyst Whitney Ijem

Analyst best performing recommendations are on KRYS (KRYSTAL BIOTECH).
The best stock recommendation documented was for KRYS (KRYSTAL BIOTECH) at 6/21/2019. The price target of $48 was fulfilled within 26 days with a profit of $18.85 (64.67%) receiving and performance score of 24.87.

Average potential price target upside

of $107.91 (50.34%) on ALNY (ALNYLAM PHARMACEUTICALS).
of $72.49 (15.18%) on VRTX (VERTEX PHARMACEUTICALS).
of $31.7 (91.22%) on RYTM (RHYTHM PHARMACEUTICALS).

SRPT Sarepta Therapeutics GBIO Generation Bio Co PASG Passage Bio RCKT Rocket Pharmaceuticals RGLS Regulus Therapeutics TNYA Tenaya Therapeutics ALNY Alnylam Pharmaceuticals BMRN Biomarin Pharmaceutical GILD Gilead Sciences KRYS Krystal Biotech RYTM Rhythm Pharmaceuticals SGMO Sangamo Therapeutics TSHA Taysha Gene Therapies VRTX Vertex Pharmaceuticals ARCT Arcturus Therapeutics Holdings NTLA Intellia Therapeutics SGTX Sigilon Therapeutics VERV Verve Therapeutics RARE Ultragenyx

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Salveen Richter (GOLDMAN SACHS)